The FN/FBA-PEG-FBA@Cur (denoted as FNC) nanogels demonstrated a targeted effect on atherosclerosis sites, attributed to the strong affinity between the RGD sequence on FN and the integrins highly expressed on the surface of plaque cells. The gene discussed is FN1; the disease is atherosclerosis.